Icon Plc Sets New 1-Year High at $53.85 (ICLR)
Icon Plc (NASDAQ:ICLR) hit a new 52-week high on Thursday , American Banking News.com reports. The company traded as high as $53.85 and last traded at $53.56, with a volume of 267,614 shares. The stock had previously closed at $52.36.
ICLR has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Icon Plc from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 13th. They now have a $54.10 price target on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Icon Plc in a research note on Monday, August 4th. They now have a $60.00 price target on the stock, up previously from $53.00. Finally, analysts at SunTrust reiterated a “buy” rating on shares of Icon Plc in a research note on Thursday, July 31st. They now have a $70.00 price target on the stock, up previously from $56.00. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $56.01.
The stock has a 50-day moving average of $50.37 and a 200-day moving average of $46.16. The company has a market cap of $3.319 billion and a P/E ratio of 23.82.
Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.06. The company had revenue of $376.00 million for the quarter, compared to the consensus estimate of $376.89 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts predict that Icon Plc will post $2.64 earnings per share for the current fiscal year.
ICON public limited company (NASDAQ:ICLR) is a contract research organization (CRO) providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.